Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9QPI0
|
|||
| Drug Name |
AMG 794
|
|||
| Drug Type |
Bispecific T-cell engager
|
|||
| Indication | Aggressive cancer [ICD-11: 2A00-2F9Z; ICD-10: R45.6; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Claudin-6 (CLDN6) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05317078) Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.